Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BMRA (Biomerica) -- Ignore unavailable to you. Want to Upgrade?

To: Radam who wrote (66)	4/20/1998 9:26:00 AM
From: Radam	Read Replies (1) \| Respond to of 170

Here's a brief review of BMRA's results for quarter ending February 28, 1998. Sales were $2,085,773 vs 2,303,353 (a decline of 9.4%, mostly due to LANZ poor sales performance). Net income was 25,755 vs 99,857 Earnings per share were .01 vs .03 Each of the two last fiscal years BMRA has earned 0.12 per share. With one quarter left in its current fiscal year, BMRA has earned 0.05 per share. Therefore, BMRA must earn 0.07 per share this last quarter to simply perform as well as last year. The company has spent about (roughly) twice as much money on R&D this year as they did last year. This has affected earnings as much as anything. Hopefully, this investment will result in future earnings. LANZ continues to disappoint, with sales and net income both declining. It seems that only news will lift this stock in the near term, we aren't seeing enough growth to justify a higher stock price. You can review the full 10Q for both companies at freeedgar.com